

24 June 2011

'RESEARCH NEVER STOPS'

info@evotec.com | www.evotec.com

For further information,
please contact

Dr Werner Lanthaler
Chief Executive Officer
+49.(0)40.560 81-242
+49.(0)40.560 81-333 Fax
werner.lanthaler@evotec.com

Evotec AG
Schnackenburgallee 114
22525 Hamburg (Germany)

Roche Group Media Relations
Phone: +41 -61 688 8888 /
basel.mediaoffice@roche.com

- Alexander Klauser (Head)
- Silvia Dobry
- Daniel Grotzky
- Claudia Schmitt

Evotec and Roche to jointly develop biomarkers in oncology

- **AN ALLIANCE FOR PERSONALIZED HEALTHCARE IN
CANCER RESEARCH AND DEVELOPMENT**

Hamburg, Germany and Basel, Switzerland – 24 June 2011: Evotec AG (FSE: EVT, TecDAX) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a collaboration in novel protein-activity based biomarkers for Roche's oncology drugs under development. Evotec AG will employ its PhosphoScout® platform to discover protein-phosphorylation's that predict favorable dosage and efficacy of targeted cancer drugs in patients. Roche will be responsible for conducting clinical trials as well as assessing the development of companion diagnostics for patient stratification.

"We are very pleased to collaborate with Evotec AG and benefit from the PhosphoScout® technology to identify appropriate pharmacodynamics and patient stratification biomarkers," **said Mike Burgess, Global Head of Oncology, Roche Pharma Research and Exploratory Development.** "These biomarkers are core to the development of targeted therapeutics for cancer therapy."

"Biomarker-based personalized healthcare has led to a paradigm shift in cancer therapy," **said Dr. Werner Lanthaler, Chief Executive Officer of Evotec AG.** "We are proud to partner Evotec's novel biomarker concept with Roche, the world leading personalized healthcare company, and its Pharma Research and Development Organization."

Under the initial three-year term Evotec and Roche will conduct multiple biomarker programs for therapeutic antibodies or small molecule inhibitors. Evotec will receive undisclosed up-front and success-based payments for each program.

About the PhosphoScout® platform

Evotec's PhosphoScout® platform employs high-end mass spectrometry to identify and quantify thousands of cellular phosphorylation events on a global scale. Unlike immunoassays, PhosphoScout® allows truly unbiased systems-wide profiling of signalling pathways. Monitoring changes in the cellular phosphoproteome in response to drug treatment not only supports mechanistic understanding of targeted drugs but also enables the discovery of predictive biomarkers.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-

of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. For additional information please go to www.evotec.com

ABOUT ROCHE

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in *in-vitro* diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

FORWARD-LOOKING STATEMENTS — *Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*